APEI outlines $81M–$88M adjusted EBITDA target for 2025 amid business simplification and enrollment growth APEI outlines $81M–$88M adjusted EBITDA target for 2025 amid business simplification and enrollment growth Post ContentapeiRead More You might also be interested in reading Ovid Therapeutics GAAP EPS of -$0.06, revenue of $6.3M. August 7, 2025 In Mainstream ← Previous post Next post →